WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond

Join Dr. Andrew Lewis, Chief Scientific Officer, and Dr. Stuart Mair, Chief Medical Officer, in our upcoming webinar as we explore the latest developments in orally delivered GLP-1 agonists and take a look at potential future innovations.

Our expert speakers will examine obesity as a global health issue, discussing its profound impact on healthcare. They will guide us through the discovery of GLP-1 agonists as potential treatments for type 2 diabetes; the incredible potential for these therapeutics outside diabetes and explore the challenges and potential solutions for orally products. The webinar will highlight Quotient Sciences’ Translational Pharmaceutics® platform and describe how it has enabled the accelerated development of both orally delivered peptides and small molecules in the incretin family.

This engaging session will cover:

– Drivers for oral incretin analogues

– CMC and clinical challenges in their development

– Future innovation

We will be taking questions ahead of the webinar so please submit directly to events@quotientsciences.com

Don’t miss this opportunity to stay at the forefront of treatment advancements in this quickly evolving category.